First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly ‘unfrail’ patients with advanced non-small-cell lung cancer: ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-12

AUTHORS

C. Tibaldi, A. Camerini, A. D’Incecco, E. Vasile, A. Fabbri, D. Amoroso, F. Cappuzzo

ABSTRACT

PURPOSE: The role of cisplatin in the first-line treatment for elderly advanced non-small-cell lung cancer is not completely defined. We previously reported in this subset of patients an interesting efficacy and tolerability of a sequential schedule of gemcitabine followed by docetaxel. METHODS: Patients aged ≥70 years and with Eastern Cooperative Oncology Group performance status 0 or 1 received cisplatin 60 mg/m(2) on Day 1 and gemcitabine 1,000 mg/m(2) on Day 1 and 8 every 3 weeks for 3 courses followed by 3 courses of docetaxel 37.5 mg/m(2) on Day 1 and 8 every 3 weeks, provided there was no evidence of disease progression. Patients were excluded if considered 'frail' according to the Multidimensional Geriatric Assessment. The main objective of the study was the 4-month progression-free survival rate. Simon's two-stage minimax design was applied to calculate the sample size. RESULTS: After 30 patients were enroled into the study, the 4-month progression-free survival rate was 53.3 % and the study was closed at the first stage for futility; the overall response rate was 16.7 %; the median time to progression and median duration of survival were 5.1 and 8.6 months, respectively; the 1-year survival rate was 30 %. CONCLUSION: The incorporation of cisplatin in a sequential schedule of gemcitabine followed by docetaxel is feasible but did not yield a substantial advantage to deserve further investigations. More... »

PAGES

2003-2008

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00432-012-1280-5

DOI

http://dx.doi.org/10.1007/s00432-012-1280-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037201771

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22767317


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Presidio Ospedaliero", 
          "id": "https://www.grid.ac/institutes/grid.440387.c", 
          "name": [
            "Division of Oncology, Department of Oncology, Civil Hospital, viale Alfieri 36, 57100, Livorno, Italy", 
            "U.O. Oncologia Medica, Presidio Ospedaliero, viale Alfieri 36, 57100, Livorno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tibaldi", 
        "givenName": "C.", 
        "id": "sg:person.0631427704.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631427704.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedaliero di Castelfranco Veneto", 
          "id": "https://www.grid.ac/institutes/grid.417115.7", 
          "name": [
            "Division of Oncology, Department of Oncology, Civil Hospital, via Aurelia 335, 55043, Viareggio, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Camerini", 
        "givenName": "A.", 
        "id": "sg:person.01154065224.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154065224.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedaliero di Castelfranco Veneto", 
          "id": "https://www.grid.ac/institutes/grid.417115.7", 
          "name": [
            "Division of Oncology, Department of Oncology, Civil Hospital, viale Alfieri 36, 57100, Livorno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "D\u2019Incecco", 
        "givenName": "A.", 
        "id": "sg:person.01152336274.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152336274.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale di Parma", 
          "id": "https://www.grid.ac/institutes/grid.411482.a", 
          "name": [
            "Department of Oncology, Azienda Ospedaliero-Universitaria, via Roma 67, 57100, Pisa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vasile", 
        "givenName": "E.", 
        "id": "sg:person.01006607213.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006607213.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedaliero di Castelfranco Veneto", 
          "id": "https://www.grid.ac/institutes/grid.417115.7", 
          "name": [
            "Division of Pneumology, Civil Hospital, viale Matteotti 9, 51100, Pistoia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fabbri", 
        "givenName": "A.", 
        "id": "sg:person.0722546444.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722546444.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedaliero di Castelfranco Veneto", 
          "id": "https://www.grid.ac/institutes/grid.417115.7", 
          "name": [
            "Division of Oncology, Department of Oncology, Civil Hospital, via Aurelia 335, 55043, Viareggio, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amoroso", 
        "givenName": "D.", 
        "id": "sg:person.0611155055.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611155055.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedaliero di Castelfranco Veneto", 
          "id": "https://www.grid.ac/institutes/grid.417115.7", 
          "name": [
            "Division of Oncology, Department of Oncology, Civil Hospital, viale Alfieri 36, 57100, Livorno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cappuzzo", 
        "givenName": "F.", 
        "id": "sg:person.01016401166.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016401166.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/jnci/djk196", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002888701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.5622", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012862395"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012950363", 
          "https://doi.org/10.1038/sj.bjc.6604187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.12.5708", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015098075"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/94.3.173", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015947313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdm084", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016801095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.09.053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017113154"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2010.05.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018308276"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0021-9681(87)90171-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020988115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2007.02.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023252698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.8485", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024396986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800050689", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027902612", 
          "https://doi.org/10.1007/s002800050689"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)60780-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028009722"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(03)00062-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033059601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e318197f4ff", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044799728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.7509", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083948754"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-12", 
    "datePublishedReg": "2012-12-01", 
    "description": "PURPOSE: The role of cisplatin in the first-line treatment for elderly advanced non-small-cell lung cancer is not completely defined. We previously reported in this subset of patients an interesting efficacy and tolerability of a sequential schedule of gemcitabine followed by docetaxel.\nMETHODS: Patients aged\u00a0\u226570\u00a0years and with Eastern Cooperative Oncology Group performance status 0 or 1 received cisplatin 60\u00a0mg/m(2) on Day 1 and gemcitabine 1,000\u00a0mg/m(2) on Day 1 and 8 every 3\u00a0weeks for 3 courses followed by 3 courses of docetaxel 37.5\u00a0mg/m(2) on Day 1 and 8 every 3\u00a0weeks, provided there was no evidence of disease progression. Patients were excluded if considered 'frail' according to the Multidimensional Geriatric Assessment. The main objective of the study was the 4-month progression-free survival rate. Simon's two-stage minimax design was applied to calculate the sample size.\nRESULTS: After 30 patients were enroled into the study, the 4-month progression-free survival rate was 53.3\u00a0% and the study was closed at the first stage for futility; the overall response rate was 16.7\u00a0%; the median time to progression and median duration of survival were 5.1 and 8.6\u00a0months, respectively; the 1-year survival rate was 30\u00a0%.\nCONCLUSION: The incorporation of cisplatin in a sequential schedule of gemcitabine followed by docetaxel is feasible but did not yield a substantial advantage to deserve further investigations.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00432-012-1280-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "138"
      }
    ], 
    "name": "First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly \u2018unfrail\u2019 patients with advanced non-small-cell lung cancer: a multicenter phase II study", 
    "pagination": "2003-2008", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b13740f77445dcc1119ae7ede4be541933995181dd845ce77f697755d78ffc27"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22767317"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7902060"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00432-012-1280-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037201771"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00432-012-1280-5", 
      "https://app.dimensions.ai/details/publication/pub.1037201771"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000482.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00432-012-1280-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-012-1280-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-012-1280-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-012-1280-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-012-1280-5'


 

This table displays all metadata directly associated to this object as RDF triples.

230 TRIPLES      21 PREDICATES      60 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00432-012-1280-5 schema:about N0c7c7803aa2f4a4abf8b2abf3530b598
2 N1e227afabe5d40beafd01dad00bc9c8f
3 N2d397c5819b243c292e1c88047b0c2da
4 N33cdb740ef834086a2ba1ebe18f58af9
5 N3427cafbc7b74ecfa1160306de9e8156
6 N504ed4e6f36748639507dc7cf65f548f
7 N5de2ecf449104ff5a59f7e449965d244
8 N5e93e348d4c845cfafcf006874005e3f
9 N6f1474c331064919af7ee87c868e8157
10 N8bb55a1cb6804557bf92c9d26fa65972
11 N9e33c7608696472db503b7c13cba85bd
12 Naa0f525e9a1946018acc20679fcd24c2
13 Nb1b2d7b684474e2ca20d689b8af88766
14 Ncf6fd50150384a548f20fcda77a28aa9
15 Ne870cb13df8c42f7844cbb46f571f1b5
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author Na8d87e1d92b44a7cb29258f1a41fc197
19 schema:citation sg:pub.10.1007/s002800050689
20 sg:pub.10.1038/sj.bjc.6604187
21 https://doi.org/10.1016/0021-9681(87)90171-8
22 https://doi.org/10.1016/j.ejca.2007.02.004
23 https://doi.org/10.1016/j.lungcan.2010.05.007
24 https://doi.org/10.1016/s0140-6736(11)60780-0
25 https://doi.org/10.1016/s0959-8049(03)00062-5
26 https://doi.org/10.1093/annonc/mdm084
27 https://doi.org/10.1093/jnci/94.3.173
28 https://doi.org/10.1093/jnci/djk196
29 https://doi.org/10.1097/jto.0b013e318197f4ff
30 https://doi.org/10.1200/jco.2004.09.053
31 https://doi.org/10.1200/jco.2007.12.5708
32 https://doi.org/10.1200/jco.2009.23.5622
33 https://doi.org/10.1200/jco.2009.23.8485
34 https://doi.org/10.1200/jco.2011.29.15_suppl.7509
35 schema:datePublished 2012-12
36 schema:datePublishedReg 2012-12-01
37 schema:description PURPOSE: The role of cisplatin in the first-line treatment for elderly advanced non-small-cell lung cancer is not completely defined. We previously reported in this subset of patients an interesting efficacy and tolerability of a sequential schedule of gemcitabine followed by docetaxel. METHODS: Patients aged ≥70 years and with Eastern Cooperative Oncology Group performance status 0 or 1 received cisplatin 60 mg/m(2) on Day 1 and gemcitabine 1,000 mg/m(2) on Day 1 and 8 every 3 weeks for 3 courses followed by 3 courses of docetaxel 37.5 mg/m(2) on Day 1 and 8 every 3 weeks, provided there was no evidence of disease progression. Patients were excluded if considered 'frail' according to the Multidimensional Geriatric Assessment. The main objective of the study was the 4-month progression-free survival rate. Simon's two-stage minimax design was applied to calculate the sample size. RESULTS: After 30 patients were enroled into the study, the 4-month progression-free survival rate was 53.3 % and the study was closed at the first stage for futility; the overall response rate was 16.7 %; the median time to progression and median duration of survival were 5.1 and 8.6 months, respectively; the 1-year survival rate was 30 %. CONCLUSION: The incorporation of cisplatin in a sequential schedule of gemcitabine followed by docetaxel is feasible but did not yield a substantial advantage to deserve further investigations.
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree false
41 schema:isPartOf N1dc8d7bad8274d43a4f4376c0bd3a05f
42 N372a22912240427aa97598f6561ddbbd
43 sg:journal.1313647
44 schema:name First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly ‘unfrail’ patients with advanced non-small-cell lung cancer: a multicenter phase II study
45 schema:pagination 2003-2008
46 schema:productId N4c87b08768d24fd483aae13f8060834c
47 N5da88b58603c4d80a565ae2ba2a16929
48 N79c281da21524072acf358dafb262e75
49 Nb5fba76244a44b49af82a9bf495ab67b
50 Ndfbb7151234348b98973b009070c657b
51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037201771
52 https://doi.org/10.1007/s00432-012-1280-5
53 schema:sdDatePublished 2019-04-10T21:30
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher Nc58db77134f24319bc8f1515a97de7fe
56 schema:url http://link.springer.com/10.1007/s00432-012-1280-5
57 sgo:license sg:explorer/license/
58 sgo:sdDataset articles
59 rdf:type schema:ScholarlyArticle
60 N0c7c7803aa2f4a4abf8b2abf3530b598 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Cisplatin
62 rdf:type schema:DefinedTerm
63 N1dc8d7bad8274d43a4f4376c0bd3a05f schema:issueNumber 12
64 rdf:type schema:PublicationIssue
65 N1e227afabe5d40beafd01dad00bc9c8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Carcinoma, Non-Small-Cell Lung
67 rdf:type schema:DefinedTerm
68 N2d397c5819b243c292e1c88047b0c2da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Drug Administration Schedule
70 rdf:type schema:DefinedTerm
71 N33cdb740ef834086a2ba1ebe18f58af9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Disease-Free Survival
73 rdf:type schema:DefinedTerm
74 N3427cafbc7b74ecfa1160306de9e8156 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Treatment Outcome
76 rdf:type schema:DefinedTerm
77 N372a22912240427aa97598f6561ddbbd schema:volumeNumber 138
78 rdf:type schema:PublicationVolume
79 N4c87b08768d24fd483aae13f8060834c schema:name dimensions_id
80 schema:value pub.1037201771
81 rdf:type schema:PropertyValue
82 N504ed4e6f36748639507dc7cf65f548f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Antineoplastic Combined Chemotherapy Protocols
84 rdf:type schema:DefinedTerm
85 N55b55d2e4e164652b5c233860b949614 rdf:first sg:person.01154065224.96
86 rdf:rest N63b8afee30df44ddb1f268d41a1c1d1d
87 N5da88b58603c4d80a565ae2ba2a16929 schema:name nlm_unique_id
88 schema:value 7902060
89 rdf:type schema:PropertyValue
90 N5de2ecf449104ff5a59f7e449965d244 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Female
92 rdf:type schema:DefinedTerm
93 N5e93e348d4c845cfafcf006874005e3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Male
95 rdf:type schema:DefinedTerm
96 N63b8afee30df44ddb1f268d41a1c1d1d rdf:first sg:person.01152336274.29
97 rdf:rest N96a46a0f0d824c8d8e302989ddea6006
98 N665442108cd942a5bfad485e8442287f rdf:first sg:person.0722546444.94
99 rdf:rest N94f39598bf0647f39643ab9a64b2534e
100 N6f1474c331064919af7ee87c868e8157 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Humans
102 rdf:type schema:DefinedTerm
103 N79c281da21524072acf358dafb262e75 schema:name doi
104 schema:value 10.1007/s00432-012-1280-5
105 rdf:type schema:PropertyValue
106 N8bb55a1cb6804557bf92c9d26fa65972 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Aged
108 rdf:type schema:DefinedTerm
109 N94f39598bf0647f39643ab9a64b2534e rdf:first sg:person.0611155055.35
110 rdf:rest Nabc0c47b251e4ccfb276c7f2277c5c36
111 N96a46a0f0d824c8d8e302989ddea6006 rdf:first sg:person.01006607213.66
112 rdf:rest N665442108cd942a5bfad485e8442287f
113 N9e33c7608696472db503b7c13cba85bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Survival Rate
115 rdf:type schema:DefinedTerm
116 Na8d87e1d92b44a7cb29258f1a41fc197 rdf:first sg:person.0631427704.49
117 rdf:rest N55b55d2e4e164652b5c233860b949614
118 Naa0f525e9a1946018acc20679fcd24c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Lung Neoplasms
120 rdf:type schema:DefinedTerm
121 Nabc0c47b251e4ccfb276c7f2277c5c36 rdf:first sg:person.01016401166.40
122 rdf:rest rdf:nil
123 Nb1b2d7b684474e2ca20d689b8af88766 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Taxoids
125 rdf:type schema:DefinedTerm
126 Nb5fba76244a44b49af82a9bf495ab67b schema:name pubmed_id
127 schema:value 22767317
128 rdf:type schema:PropertyValue
129 Nc58db77134f24319bc8f1515a97de7fe schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 Ncf6fd50150384a548f20fcda77a28aa9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Aged, 80 and over
133 rdf:type schema:DefinedTerm
134 Ndfbb7151234348b98973b009070c657b schema:name readcube_id
135 schema:value b13740f77445dcc1119ae7ede4be541933995181dd845ce77f697755d78ffc27
136 rdf:type schema:PropertyValue
137 Ne870cb13df8c42f7844cbb46f571f1b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Deoxycytidine
139 rdf:type schema:DefinedTerm
140 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
141 schema:name Medical and Health Sciences
142 rdf:type schema:DefinedTerm
143 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
144 schema:name Clinical Sciences
145 rdf:type schema:DefinedTerm
146 sg:journal.1313647 schema:issn 0171-5216
147 1432-1335
148 schema:name Journal of Cancer Research and Clinical Oncology
149 rdf:type schema:Periodical
150 sg:person.01006607213.66 schema:affiliation https://www.grid.ac/institutes/grid.411482.a
151 schema:familyName Vasile
152 schema:givenName E.
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006607213.66
154 rdf:type schema:Person
155 sg:person.01016401166.40 schema:affiliation https://www.grid.ac/institutes/grid.417115.7
156 schema:familyName Cappuzzo
157 schema:givenName F.
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016401166.40
159 rdf:type schema:Person
160 sg:person.01152336274.29 schema:affiliation https://www.grid.ac/institutes/grid.417115.7
161 schema:familyName D’Incecco
162 schema:givenName A.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152336274.29
164 rdf:type schema:Person
165 sg:person.01154065224.96 schema:affiliation https://www.grid.ac/institutes/grid.417115.7
166 schema:familyName Camerini
167 schema:givenName A.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154065224.96
169 rdf:type schema:Person
170 sg:person.0611155055.35 schema:affiliation https://www.grid.ac/institutes/grid.417115.7
171 schema:familyName Amoroso
172 schema:givenName D.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611155055.35
174 rdf:type schema:Person
175 sg:person.0631427704.49 schema:affiliation https://www.grid.ac/institutes/grid.440387.c
176 schema:familyName Tibaldi
177 schema:givenName C.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631427704.49
179 rdf:type schema:Person
180 sg:person.0722546444.94 schema:affiliation https://www.grid.ac/institutes/grid.417115.7
181 schema:familyName Fabbri
182 schema:givenName A.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722546444.94
184 rdf:type schema:Person
185 sg:pub.10.1007/s002800050689 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027902612
186 https://doi.org/10.1007/s002800050689
187 rdf:type schema:CreativeWork
188 sg:pub.10.1038/sj.bjc.6604187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012950363
189 https://doi.org/10.1038/sj.bjc.6604187
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/0021-9681(87)90171-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020988115
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/j.ejca.2007.02.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023252698
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/j.lungcan.2010.05.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018308276
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1016/s0140-6736(11)60780-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028009722
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/s0959-8049(03)00062-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033059601
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1093/annonc/mdm084 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016801095
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1093/jnci/94.3.173 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015947313
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1093/jnci/djk196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002888701
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1097/jto.0b013e318197f4ff schema:sameAs https://app.dimensions.ai/details/publication/pub.1044799728
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1200/jco.2004.09.053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017113154
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1200/jco.2007.12.5708 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015098075
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1200/jco.2009.23.5622 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012862395
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1200/jco.2009.23.8485 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024396986
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1200/jco.2011.29.15_suppl.7509 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083948754
218 rdf:type schema:CreativeWork
219 https://www.grid.ac/institutes/grid.411482.a schema:alternateName Ospedale di Parma
220 schema:name Department of Oncology, Azienda Ospedaliero-Universitaria, via Roma 67, 57100, Pisa, Italy
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.417115.7 schema:alternateName Ospedaliero di Castelfranco Veneto
223 schema:name Division of Oncology, Department of Oncology, Civil Hospital, via Aurelia 335, 55043, Viareggio, Italy
224 Division of Oncology, Department of Oncology, Civil Hospital, viale Alfieri 36, 57100, Livorno, Italy
225 Division of Pneumology, Civil Hospital, viale Matteotti 9, 51100, Pistoia, Italy
226 rdf:type schema:Organization
227 https://www.grid.ac/institutes/grid.440387.c schema:alternateName Presidio Ospedaliero
228 schema:name Division of Oncology, Department of Oncology, Civil Hospital, viale Alfieri 36, 57100, Livorno, Italy
229 U.O. Oncologia Medica, Presidio Ospedaliero, viale Alfieri 36, 57100, Livorno, Italy
230 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...